These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29968076)

  • 21. Understanding genetic determinants of resistance to immune checkpoint blockers.
    Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S
    Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of combining radiotherapy with immune-checkpoint inhibition.
    Hwang WL; Pike LRG; Royce TJ; Mahal BA; Loeffler JS
    Nat Rev Clin Oncol; 2018 Aug; 15(8):477-494. PubMed ID: 29872177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.
    Qin BD; Jiao XD; Zang YS
    Med Hypotheses; 2018 Jul; 116():111-113. PubMed ID: 29857892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
    Barlesi F; Tomasini P
    Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudoprogression and hyperprogression after checkpoint blockade.
    Wang Q; Gao J; Wu X
    Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
    Sehgal A; Whiteside TL; Boyiadzis M
    Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
    Gill DM; Agarwal N
    Urol Oncol; 2017 Dec; 35(12):676-677. PubMed ID: 29054496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
    Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
    FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.
    Wilmott JS; Rizos H; Scolyer RA; Long GV
    Clin Cancer Res; 2017 Jun; 23(12):2921-2923. PubMed ID: 28468948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.